Maura N Dickler MD
Breast Cancer
VP, Breast and Gyne Oncology, Product Development, Genentech
Join to View Full Profile
One DNA WaySouth San Francisco, CA 94080
Dr. Dickler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
University of ChicagoResidency, Internal Medicine, 1991 - 1994
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1991
Certifications & Licensure
NY State Medical License 1995 - 2026
IL State Medical License 1991 - 1996- IL State Medical License 1991 - 1996
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 5 citationsAn Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.Sarat Chandarlapaty, Maura N Dickler, Jose Alejandro Perez Fidalgo, Rafael Villanueva-Vázquez, Jennifer Giltnane
Clinical Cancer Research. 2023-08-01 - 7 citationsGenome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimensJulia C F Quintanilha, Jin Wang, Alexander B. Sibley, Wei Xu, Osvaldo Espin-Garcia
International Journal of Cancer. 2022-01-15 - 5 citationsA clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapyMei Yin C. Polley, Maura N. Dickler, Jason P. Sinnwell, Kathleen S. Tenner, Juan de la Haba
Breast Cancer Research and Treatment. 2021-07-03
Authored Content
- A Phase IIA Trial of Acupuncture to Reduce Chemotherapy-Induced PeripheralAugust 2018
Press Mentions
NCCN Patient Advocacy Summit Emphasizes Treating Every Cancer Patient as an IndividualDecember 10th, 2020- Grantees Awarded as Part of the Breast Cancer Research Project Between NCCN and Lilly OncologyDecember 3rd, 2020
FDA ODAC Votes on Safety and Efficacy of Ramucirumab plus Erlotinib for EGFR+ NSCLCFebruary 27th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
